No, we still think the CEO should not serve as BoD Chair. Actually, we think CEOs should not even serve on the BoD. Now, more than before, we think investors should make it a priority.
A few months ago, we identified only two-and-a-half priorities for investors: eliminate poison pills, destagger BoDs, and (maybe) achieve proxy access. We dismissed many others, including majority voting, pay disclosure, political contribution disclosure ... and separating the CEO and BoD Chair roles. Recent events in the Allergan situation changed our mind.